Cargando…

Pembrolizumab-induced psoriatic arthritis treated with disease-modifying anti-rheumatic drugs in a patient with gastric cancer: A case report

BACKGROUND: Immune checkpoint inhibitor (ICI)-induced rheumatic immune-related adverse events (irAEs) have been infrequently reported, and the treatment of severe or refractory arthritis as irAEs has not been established yet. CASE SUMMARY: The patient was a 67-year-old man with a history of well-con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Sehan, Sun, Jong Hee, Kim, Hongsik, Kim, Hee Kyung, Yang, Yaewon, Lee, Jun Su, Choi, In Ah, Han, Hye Sook
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9846987/ https://www.ncbi.nlm.nih.gov/pubmed/36687173 http://dx.doi.org/10.12998/wjcc.v11.i1.218

Ejemplares similares

Sequential spinal and intracranial dural metastases in gastric adenocarcinoma: A case report
por: Kim, Hongsik, et al.
Publicado: (2018)

Discordance in HER2 status between primary gastric adenocarcinoma tumors and cells from the corresponding malignant effusions
por: Kim, Hongsik, et al.
Publicado: (2019)

Psoriatic Arthritis and Metabolic Syndrome: Is There a Role for Disease Modifying Anti-Rheumatic Drugs?
por: Atzeni, Fabiola, et al.
Publicado: (2021)

Comparison of remission criteria in patients with rheumatoid arthritis treated with biologic or targeted synthetic disease-modifying anti-rheumatic drugs: results from a nationwide registry
por: Koh, Jung Hee, et al.
Publicado: (2022)

Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
por: Simon, David, et al.
Publicado: (2019)

Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis
por: Min, Hong Ki, et al.
Publicado: (2022)

Distinct tumor immune microenvironments in primary and metastatic lesions in gastric cancer patients
por: Son, Seung-Myoung, et al.
Publicado: (2020)

Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review
por: Jung, Ju-Yang, et al.
Publicado: (2018)

Screening for Psoriatic Arthritis in Korean Psoriasis Patients Using the Psoriatic Arthritis Screening Evaluation Questionnaire
por: You, Hyang-Suk, et al.
Publicado: (2015)

Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
por: Deyab, Gia, et al.
Publicado: (2017)

Association of Behçet disease with psoriasis and psoriatic arthritis
por: Hahn, Hyung Jin, et al.
Publicado: (2021)

Conventional Synthetic Disease-Modifying Anti-rheumatic Drugs for Psoriatic Arthritis: Findings and Implications From a Patient Centered Longitudinal Study in Brazil
por: Faria, Ronaldo José, et al.
Publicado: (2022)

Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective
por: Lubrano, Ennio, et al.
Publicado: (2022)

DGEMRIC in the Assessment of Pre-Morphological Cartilage Degeneration in Rheumatic Disease: Rheumatoid Arthritis vs. Psoriatic Arthritis
por: Abrar, Daniel B., et al.
Publicado: (2021)

Long-term Survival after Repeated Local Therapy and Salvage Chemotherapy for Recurrent Metastases from Gastric Cancer: a Case Report and Literature Review
por: Kwon, Jihyun, et al.
Publicado: (2018)

Difficult to Treat and Refractory to Treatment in Psoriatic Arthritis
por: Lubrano, Ennio, et al.
Publicado: (2023)

Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2020)

A Case of Ostraceous Psoriasis with Psoriatic Arthritis in an AIDS Patient
por: Park, Minkee, et al.
Publicado: (2018)

Tuberculosis in Children with Rheumatic Diseases Treated with Biologic Disease-Modifying Anti-Rheumatic Drugs
por: Kavadichanda, Chengappa, et al.
Publicado: (2021)

Psoriatic arthritis
por: Sankowski, Artur Jacek, et al.
Publicado: (2013)

Psoriatic Arthritis
por: Fitzgerald, Kara, et al.
Publicado: (2012)

Psoriatic arthritis
por: Ocampo D, Vanessa, et al.
Publicado: (2019)

Macrophage dysfunction in Psoriatic Arthritis
por: Wenink, Mark H, et al.
Publicado: (2011)

Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
por: Tawaratsumida, Hiroki, et al.
Publicado: (2017)

Outcomes with Biological Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in Older Patients Treated for Rheumatoid Arthritis
por: Akter, Ripa, et al.
Publicado: (2020)

Treating psoriatic arthritis: how effective are TNF antagonists?
por: Gottlieb, Alice B, et al.
Publicado: (2004)

Antinuclear Antibodies in Patients with Psoriatic Arthritis Treated or Not with Biologics
por: Silvy, Florent, et al.
Publicado: (2015)

Diagnosing Psoriatic Arthritis from the Dermatologist’s View
por: Cho, Hyun-Ho, et al.
Publicado: (2013)

The Anxiety and Depression in Rheumatoid Arthritis Patients Treating with Disease-Modifying Anti-Rheumatic Drugs during the COVID-19 Pandemic
por: Sargın, Gökhan, et al.
Publicado: (2022)

Rheumatic diseases, rheumatism and arthritis
por: Brugsch, Heinrich Georg, 1903-
Publicado: (1957)

Effectiveness of inactivated influenza vaccine in autoimmune rheumatic diseases treated with disease-modifying anti-rheumatic drugs
por: Nakafero, Georgina, et al.
Publicado: (2020)

Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
por: Cantini, Fabrizio, et al.
Publicado: (2009)

Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer
por: Jeon, Eun Kyoung, et al.
Publicado: (2011)

Implementation of the Treat-to-Target Concept in Evaluation of Psoriatic Arthritis Patients
por: Gazitt, Tal, et al.
Publicado: (2021)

Psoriatic arthritis with hyperuricemia: more peripheral, destructive, and challenging to treat
por: Widawski, L., et al.
Publicado: (2022)

Psoriatic Arthritis: An Update
por: Lloyd, Peter, et al.
Publicado: (2012)

The Risk of Systemic Diseases in Those with Psoriasis and Psoriatic Arthritis: From Mechanisms to Clinic
por: Woo, Yu Ri, et al.
Publicado: (2020)

Exosomal miR-181b-5p Downregulation in Ascites Serves as a Potential Diagnostic Biomarker for Gastric Cancer-associated Malignant Ascites
por: Yun, Jieun, et al.
Publicado: (2019)

Prediction of remission and low disease activity in disease-modifying anti-rheumatic drug-refractory patients with rheumatoid arthritis treated with golimumab
por: Vastesaeger, Nathan, et al.
Publicado: (2016)

Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis
por: Svedbom, Axel, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9pugv3o0diha1ql0d4iqsnpmv0